Showing results (101-110 of 139) with videos related to
Sort By:
Pageof 14
Haematologica|December 17, 2016
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patientsBlanca Scheijen, Judith M Boer, René Marke, et al.Blood|April 22, 2020
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemiaAmir Enshaei, David O'Connor, Jack Bartram, et al.Ebiomedicine|May 29, 2024
An artificial intelligence-assisted clinical framework to facilitate diagnostics and translational discovery in hematologic neoplasiaMing Tang, Željko Antić, Pedram Fardzadeh, et al.The Lancet. Haematology|September 24, 2021
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort studyNaomi Michels, Judith M Boer, Amir Enshaei, et al.The Lancet. Oncology|July 25, 2017
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group studyBenjamin O Wolthers, Thomas L Frandsen, André Baruchel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2019
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized StudyRob Pieters, Paola De Lorenzo, Philip Ancliffe, et al.Journal of Pediatric Hematology/Oncology|February 28, 2022
Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic LeukemiaRikke L Nielsen, Benjamin O Wolthers, Marianne Helenius, et al.EMBO Molecular Medicine|November 4, 2018
PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemiaPaulina Richter-Pechańska, Joachim B Kunz, Beat Bornhauser, et al.BMC Cancer|May 3, 2022
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocolLinea Natalie Toksvang, Bodil Als-Nielsen, Christopher Bacon, et al.Blood|June 30, 2021
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno ConsortiumSwantje Buchmann, Martin Schrappe, Andre Baruchel, et al.Pageof 14